Haemonetics HAE recently gained FDA’s 510(k) clearance for its next-generation Intelligent Control Software for Cell Saver Elite+ Autotransfusion System. The approval was followed by a full market release of the same.
According to Haemonetics, this software upgrade offers customers key enhancements to help simplify operations, while enhancing efficiency and improving user experience.
The latest development is expected to upgrade Haemonetics’ Cell Salvage platform and broaden the company’s scope in the growing autotransfusion space.
A Few Words on The Cell Saver Elite+
This autotransfusion system, with its advanced technology, helps hospitals to recover a patient's blood during surgical procedures with the potential for medium-to-high blood loss. This in turn helps to avoid unnecessary allogeneic transfusions while reducing related procedure costs.
Image Source: Zacks Investment Research
This Intelligent Control software has more than 50 automation enhancements for a better user experience. These include complete user control with a "Manual Mode" option, expanded wash volumes adjustable to the Association for the Advancement of Blood & Biotherapies (AABB) recommended levels, and enhanced emergency options.
Market Prospects
Going by a Mordor Intelligence report, the auto-transfusion systems market is projected to witness a CAGR of 5.2% from 2019 to 2027. Per the report, the initial phase of the COVID-19 pandemic lowered the demand for auto-transfusion systems, thereby impacting the market's overall growth. However, the resumption of surgeries after the relaxation of regulations increased demand for autotransfusion systems. The current scenario is expected to drive the growth of the market over the forecast period.
Haemonetics' Recent Updates
Haemonetics has been witnessing strong growth in the Plasma franchise for quite some time. In the global plasma market, Haemonetics holds approximately 80% share. Haemonetics is currently witnessing plasma market growth above historic rates, driven by an industry striving to double collections by 2025 and the rising demand for plasma-based medicines. The company continued to benefit from the NexSys device and NexLynk donor management software (DMS), backed by increased customer adoptions.
Under the Hospital business, Hemostasis Management is witnessing strong growth over the past few quarters. The recently-acquired Vascular Closure business continues to excel. Vascular Closure represents the company’s largest hospital growth opportunity. The company is currently focusing on accelerating its penetration into the $2.8 billion U.S. market by pursuing regulatory approvals to drive international expansion and strengthen its product portfolio via pipeline innovation and inorganic investments.
In Blood Center, the environment for this business continues to be challenging. However, the company remains focused on providing innovative products, leveraging on the strength of its supply chain and technology to increase market share.
Share Price Performance
Over the past six months, Haemonetics has outperformed its industry. The stock has gained 4.3% compared with the industry's 3.1% rise.
Zacks Rank and Other Key Picks
Haemonetics carries a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks in the overall healthcare sector include Hologic, Inc. HOLX, TerrAscend Corp. TRSSF and Akerna Corp. KERN. Hologic and TerrAscend both sport a Zacks Rank #1, while Akerna carries a Zack Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Hologic has an estimated long-term growth rate of 15.2%. HOLX’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 30.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Hologic has gained 10.9% against the industry’s 14.7% decline in the past year.
Estimates for TerrAscend in 2023 have remained constant at a loss of 10 cents per share in the past 30 days. Shares of TerrAscend have declined 70.6% in the past year.
TerrAscend’s earnings beat estimates in one of the last three quarters and missed the mark in the other two, with the average negative surprise being 136.11%. In the last reported quarter, TRSSF delivered an earnings surprise of 216.67%.
Akerna’s stock has declined 95.7% in the past year. Estimates for 2023 have remained constant at a loss of $1.91 per share over the past 30 days.
Akerna missed earnings estimates in each of the last four quarters, delivering a negative earnings surprise of 15.49% on average. In the last reported quarter, KERN delivered a negative earnings surprise of 13.33%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>Hologic, Inc. (HOLX) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
Akerna Corp. (KERN) : Free Stock Analysis Report
TerrAscend Corp. (TRSSF) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
